Recent Advances and Perspectives in Cancer Drug Design

Structural basis of PROTAC cooperative recognition for selective protein degradation

(2017) Morgan S Gadd et al.   Nature Chemical Biology

The high price of anticancer drugs: origins, implications, barriers, solutions

(2017) Vinay Prasad et al.   Nature Reviews Clinical Oncology

A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling

(2016) Sai Krishna Athuluri-Divakar et al.   CELL

Innovation in the pharmaceutical industry: New estimates of R&D costs

(2016) Joseph A. DiMasi et al.   JOURNAL OF HEALTH ECONOMICS

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

(2016) P. Chen et al.   MOLECULAR CANCER THERAPEUTICS

Putting a price on cancer

(2016) Richard Sullivan et al.   Nature Reviews Clinical Oncology

Induced protein degradation: an emerging drug discovery paradigm

(2016) Ashton C. Lai et al.   NATURE REVIEWS DRUG DISCOVERY

Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

(2016) Duncan E. Scott et al.   NATURE REVIEWS DRUG DISCOVERY

Discovery of a Series of Acridinones as Mechanism-Based Tubulin Assembly Inhibitors with Anticancer Activity

(2016) Luma G. Magalhaes et al.   PLoS One

Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination

(2015) Philip Jones et al.   JOURNAL OF MEDICINAL CHEMISTRY

Catalytic in vivo protein knockdown by small-molecule PROTACs

(2015) Daniel P Bondeson et al.   Nature Chemical Biology

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

Drug Discovery and Repurposing at Memorial Sloan Kettering Cancer Center: Chemical Biology Drives Translational Medicine

(2014) Bhavneet Bhinder et al.   ACS Chemical Biology

An analysis of FDA-approved drugs for oncology

(2014) Michael S. Kinch   DRUG DISCOVERY TODAY

Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer

(2014) John M. Lambert et al.   JOURNAL OF MEDICINAL CHEMISTRY

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Phenotypic screening in cancer drug discovery — past, present and future

(2014) John G. Moffat et al.   NATURE REVIEWS DRUG DISCOVERY

Oncology Drug Discovery: Planning a Turnaround

(2014) C. Toniatti et al.   Cancer Discovery

A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments

(2013) K. Masui et al.   CARCINOGENESIS

Targeted cancer therapy – Are the days of systemic chemotherapy numbered?

(2013) Won Duk Joo et al.   MATURITAS

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress

(2012) C. M. Chapman et al.   CLINICAL CANCER RESEARCH

Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors

(2012) Elisabet Wahlberg et al.   NATURE BIOTECHNOLOGY

A novel pathway for maytansinoid release from thioether linked antibody–drug conjugates (ADCs) under oxidative conditions

(2011) Nathan Fishkin et al.   CHEMICAL COMMUNICATIONS

Discovery of a Clinical Stage Multi-Kinase Inhibitor Sodium (E)-2-{2-Methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): Synthesis, Structure–Activity Relationship, and Biological Activity

(2011) M. V. Ramana Reddy et al.   JOURNAL OF MEDICINAL CHEMISTRY

Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

(2010) Stefania Redana et al.   BMC CANCER

Microtubule-binding agents: a dynamic field of cancer therapeutics

(2010) Charles Dumontet et al.   NATURE REVIEWS DRUG DISCOVERY

Targeted cancer therapies

(2010) Saurabh Aggarwal   NATURE REVIEWS DRUG DISCOVERY

Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors

(2009) Philip Jones et al.   JOURNAL OF MEDICINAL CHEMISTRY

Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs

(2009) Peter B. Bach   NEW ENGLAND JOURNAL OF MEDICINE

Estrogen-Related Receptor α Is Critical for the Growth of Estrogen Receptor–Negative Breast Cancer

(2008) Rebecca A. Stein et al.   CANCER RESEARCH

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage

(2008) S. Giordano et al.   CURRENT MEDICINAL CHEMISTRY

Mouse xenograft models vs GEM models for human cancer therapeutics

(2008) A. Richmond et al.   Disease Models & Mechanisms

Chemistry strategies in early drug discovery: an overview of recent trends

(2008) Matteo Colombo et al.   DRUG DISCOVERY TODAY

Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress

(2008) Robert K. Oldham et al.   JOURNAL OF CLINICAL ONCOLOGY

4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1

(2008) Keith A. Menear et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs

(2007) Ravi V. J. Chari   ACCOUNTS OF CHEMICAL RESEARCH